Live Free or Die Legal
This website is not an official source of law. This website does not provide legal advice. For official legal materials, verify against the relevant court, legislature, agency, or other official source. Legal information may be incomplete, outdated, or incorrectly processed. Consult a qualified attorney for advice about a specific legal matter.

This RSA section is an unofficial mirror, is not legal advice, and may be incomplete, outdated, or incorrectly processed.

RSA 318:14-b · COVID-19 Testing

Title
XXX: OCCUPATIONS AND PROFESSIONS
Chapter
318 · PHARMACISTS AND PHARMACIES
Status
current
Official source linked
Yes
Official source Copy section link

318:14-b COVID-19 Testing. – Pharmacists may administer COVID-19 testing if the following conditions are met:

Copy link
I.

The pharmacist received adequate education and training to initiate, order, administer, and analyze COVID-19 test kits.

Copy link
II.

The COVID-19 tests are administered at a pharmacy that holds the appropriate clinical certificate under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and a New Hampshire laboratory license issued by the department of health and human services (DHHS) or DHHS waiver.

Copy link
III.

The pharmacy creates and implements policies and procedures to address the collection, storage, transport, and analysis of samples collected as a result of administering and analyzing COVID-19 test kits. Such policies and procedures shall be in accordance with the manufacturer's instructions and supplemented as needed. Source. 2021, 121:4, eff. July 9, 2021.

Copy link

Source note

Source. 2021, 121:4, eff. July 9, 2021.

Source history

  • 2021, 121:4, eff. July 9, 2021

Related materials

Bill relationships

  • 2026 HB1249 reference

    rvices and Elderly Affairs ----------------------------------------------------------------- ANALYSIS This bill amends the definition of the practice of pharmacy under RSA 318 and authorizes pharmacists to prescribe certain prescription devices necessary for the appropriate delivery or administration of a prescribed drug. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

  • 2026 HB1584 amend · effective 2027-01-01

    each operated at a surplus for the past year. In no case shall the commissioner make such certification prior to July 1, 2027. 9 New Subdivision; Drug Pricing Options. Amend RSA 318 by inserting after section 47-m the following new subdivision: Drug Pricing Options 318:47-n Notice of Drug Pricing Options. I. Every pharmacy licensed in this state shall make reasonable efforts to notify cons

  • 2026 HB1584-FN amend · effective 2027-01-01

    each operated at a surplus for the past year. In no case shall the commissioner make such certification prior to July 1, 2027. 9 New Subdivision; Drug Pricing Options. Amend RSA 318 by inserting after section 47-m the following new subdivision: Drug Pricing Options 318:47-n Notice of Drug Pricing Options. I. Every pharmacy licensed in this state shall make reasonable efforts to notify cons

  • 2026 SB504 reference · effective 2027-01-01

    including rules to enforce the requirements of this section. V. Nothing in this section shall be construed to alter the jurisdiction or authority of the board of pharmacy under RSA 318. 126-ZZ:7 Free Care and Public Benefits. I. Each licensed experimental treatment center shall allocate 2 percent of its net annual profits to support access to experimental treatments and health care for qualifyin

  • 2026 SB504-FN reference · effective 2027-01-01

    including rules to enforce the requirements of this section. V. Nothing in this section shall be construed to alter the jurisdiction or authority of the board of pharmacy under RSA 318. 126-ZZ:7 Free Care and Public Benefits. I. Each licensed experimental treatment center shall allocate 2 percent of its net annual profits to support access to experimental treatments and health care for qualifyin

  • 2026 SB665 amend · effective 2027-01-01

    s used to compensate the pharmacy benefits manager. VII. Nothing in this section shall prohibit the use of spread pricing. 13 New Subdivision; Drug Pricing Options. Amend RSA 318 by inserting after section 47-m the following new subdivision: Drug Pricing Options 318:47-n Notice of Drug Pricing Options. I. Every pharmacy licensed in this state shall make reasonable efforts to notify cons

  • 2026 SB665-FN amend · effective 2027-01-01

    s used to compensate the pharmacy benefits manager. VII. Nothing in this section shall prohibit the use of spread pricing. 13 New Subdivision; Drug Pricing Options. Amend RSA 318 by inserting after section 47-m the following new subdivision: Drug Pricing Options 318:47-n Notice of Drug Pricing Options. I. Every pharmacy licensed in this state shall make reasonable efforts to notify cons

  • 2025 HB254 reference

    ician licensed pursuant to RSA 329; (2) An osteopathic physician licensed pursuant to RSA 329; (3) An advanced practice registered nurse licensed pursuant to RSA 326-B; or (4) A pharmacist licensed pursuant to RSA 318; provided, however, that a pharmacist shall not qualify as an attending health care provider under RSA 137-M:1, II or as a consulting health care provider under RSA 137-M:1, III. (b) A "health care provider" d

  • 2025 HB63 reference

    may write a prescription, drug order, or protocol for epinephrine nasal spray or auto-injectable epinephrine for the postsecondary educational institution or independent school. IV. A pharmacist licensed under RSA 318 may dispense a valid prescription, drug order, or protocol for epinephrine nasal spray or auto-injectable epinephrine issued in the name of a postsecondary educational institution or an independent school. 200